HUTCHMED (China) (HCM) H1 2024 earnings summary

Executive summary

• Achieved $25.8 million net profit in H1 2024, with strong oncology revenue growth and robust product launches, especially for FRUZAQLAⓇ in the US and China.

• In-market sales rose 140% year-over-year to $243.3 million, driven by FRUZAQLAⓇ's US launch and growth in China.

• Maintained a strong cash position of over $800 million, supporting R&D and commercial expansion.

• Advanced global launches and regulatory filings in the US, EU, and Japan, with multiple NDAs and sNDAs under review.

• Pipeline progress includes 15+ potential NDAs/sNDAs expected in the next three years and several phase III trials initiated.

Financial highlights

• H1 2024 oncology/Immunology consolidated revenue reached $168.7 million, with marketed product revenue up 59% year-over-year to $127.8 million.

• Total consolidated revenue was $168.7 million, down 53% year-over-year due to lower Takeda milestone payments.

• R&D expenditures reduced to $95.3 million, reflecting strategic reorganization and cost control.

• Selling & admin expenses decreased to $57.8 million due to tighter spending controls.

• Maintained strong cash reserves of over $800 million as of June 30, 2024.

Outlook and guidance

• Reiterates full-year 2024 oncology/immunology consolidated revenue guidance of $300–$400 million.

• On track to become self-sustaining, with a medium-term plan for 6–7 products in China and 2–3 globally.

• Anticipates multiple new product launches and indications, including global expansion of fruquintinib and savolitinib.

• Profitability expected ahead of previous 2025 target.

• Gradual increase in R&D and commercial investments anticipated over the next few years.